Middle Eastern & African Antibody Drug Conjugates Market
Middle East & Africa Antibody Drug Conjugates Market Forecast to 2030 - Growing Strategic Partnerships to Develop Antibody Drug Conjugates and Escalating Pipeline of ADCs
26 juin 2024 04h23 HE | Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Middle East & Africa Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel"...
22157.jpg
Europe Antibody Drug Conjugates Market Forecast to 2030: Increasing Investments to Develop ADCs Fuels the European Antibody Drug Conjugates Market
07 juin 2024 03h47 HE | Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Europe Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel" report has been...
Biolojic.Design_Logo_vertical_color - resized.jpg
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
03 juin 2024 11h00 HE | Biolojic Design
Biolojic Design Enters into Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany in oncology and immunology
22157.jpg
Antibody Drug Conjugates (ADC) Size, Share & Trends Analysis Report 2024: Global Market to Surpass $24 Billion by 2030, Driven by a Strong Product Pipeline & Rising Incidence and Prevalence Of Cancer
13 mai 2024 10h22 HE | Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable,...
22157.jpg
Antibody-Drug Conjugates (ADC) Industry Overview 2024: Market to Exceed $40 Billion by 2029, Driven by Daiichi Sankyo's Enhertu, Roche's Kadcyla, Astellas Pharma, Pfizer's Padcev, & Gilead's Trodelvy
26 avr. 2024 06h59 HE | Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates (ADC): Market Overview" report has been added to ResearchAndMarkets.com's offering. The global ADC market grew from $50...
Global Single-use Assemblies Market
Global Single-use Assemblies Market Projected to Surge to USD 39.97 Billion by 2030
29 mars 2024 05h35 HE | Research and Markets
Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Global Single-use Assemblies Market Size, Share & Trends Analysis Report by Product (Bag Assemblies, Filtration Assemblies), Application...
market-digits.jpg
ADC Contract Manufacturing Market projected to reach USD 27.4 Billion by 2030, growing at a CAGR of 14.2% during the forecast period of 2023-2030 - a comprehensive study by MarketDigits Richmond, March 05, 2024 (GLOBE NEWSWIRE) -- According to a research report "ADC Contract Manufacturing Market”, by Linker (Cleavable Linker, Non-Cleavable Linkers, and Others), Application...
Elucida Oncology Logo.jpg
Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
15 févr. 2024 11h45 HE | Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno...
BioNTech und Duality
BioNTech und DualityBio starten zulassungsrelevante Phase-3-Studie mit Antikörper-Wirkstoff-Konjugat-Kandidat BNT323/DB-1303 bei metastasiertem Brustkrebs
22 janv. 2024 06h45 HE | BioNTech SE
Der Start der zulassungsrelevanten Phase-3-Studie mit BNT323/DB-1303 basiert auf positiven Daten zur Sicherheit und Wirksamkeit aus einer Phase-1/2-Studie bei Brustkrebspatientinnen und -patienten mit...
BioNTech and Duality
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
22 janv. 2024 06h45 HE | BioNTech SE
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors...